Maraviroc 150mg once-daily achieves target concentrations with atazanavir/ritonavir

The pharmacokinetics of maraviroc (150 mg once daily) and atazanavir/ritonavir (300/100 mg once-daily) were assessed in a pharmacokinetic sub-study of 15 HIV-positive volunteers.  All subjects achieved, or exceeded, the targeted maraviroc Caverage of 75 ng/ml. Steady state values for maraviroc AUC, Cmax and Cmin were 4330 ng.h/ml, 650 ng/ml and 37 ng/ml, respectively. Efficacy and safety of this combination are currently being evaluated.

Ref: Vourvahis M et al. Pharmacokinetics of QD maraviroc co-administered as part of a novel NRTI-sparing regimen with atazanavir/ritonavir in HIV treatment-naive patients. 11th PK Workshop, 2010. Abstract 37.

Links to other websites are current at date of posting but not maintained.